Among the main projects of the Department of Medical Epigenetics of the EuroEspes International Centre for Neurosciences and Genomic Medicine are:

Epigenetic biomarkers

Discovery of epigenetic biomarkers for the early detection of prevalent diseases (neurodegenerative, cardiovascular, and oncological diseases).

Epigenetics R&D

Development of a line of innovative nutraceutical products with epigenetic properties (Epinutraceuticals). These products will improve the levels of epigenetic biomarkers associated with prevalent pathological processes (Alzheimer's, Parkinson's, cardiovascular disorders, etc.).

Epigenetics R&D

Pharmacoepigenetics: Study of epigenetic changes that occur in genes involved in drug metabolism and their association with response to such treatments. For example, smoking affects the methylation of CYP1A1, which is involved in drug metabolism.

Main contributions

Thanks to research projects, the Department of Medical Epigenetics has achieved the following:

Recent scientific publications

  • Atremorine treatment regulates DNA methylation in neurodegenerative disorders: epigenetic and pharmacogenetic studies. Martínez-Iglesias O, Naidoo V, Carril JC, Carrera I, Corzo L, Rodríguez S, Alejo R, Cacabelos N, Cacabelos R. CPPM. In press.
  • Epigenetic treatment of neurodegenerative disorders. Martinez Iglesias O and Cacabelos R. Book Chapter in Histone Modifications in Therapy. Elsevier. 2020. Editors: Pedro Castelo-Branco and Carmen Jeronimo.
  • DNA methyltation in neurodegenerative and cerebrovascular disorders. Martinez Iglesias O, Carrera I, Carril JC, Fernández-Novoa L, Cacabelos N, Cacabelos R. IJMS. 2020 Mar23:21(6):2220.
  • Bioactive properties of marine and vegetal nutraceuticals on prevalent diseases. Corza L, Fernández-Novoa L, Carrera I, Martínez O, Rodríguez S, Alejo R and Cacabelos R. Nutrients. 2020 12(3):747.
  • Neuroprotection with natural antioxidants in the context of Neurodegeneration: The epigenetic connection. Carrera I, Martínez O and Cacabelos R. Current Topics in Medicinal Chemistry. 2019 19(32):2999-3011.
  • Pharmacoepigenomic interventions as novel potential treatments for Alzheimer's and Parkinson's Diseases. Teijido O and Cacabelos R. Int J Mol Sci. 2018 19(10):3199
  • Pharmacogenetics of vascular risk factors in Alzheimer's Disease. Cacabelos R, Mayyazhagan A, Carril JC, Cacabelos P, Teijido O. J Pers Med. 2018 8(1):3
  • Population-based study of risk polymorphisms associated with vascular disorders and dementia. Teijido O, Carril JC, Cacabelos R. Curr Genomics. 2017. 18(5):430-441


Leave us your contact information and we will contact you.

Leave us your contact information and we will contact you.